Interleukin-1 Inhibitors and Dacryoadenitis in Adult-Onset Still Disease

Ann Intern Med. 2018 Mar 20;168(6):455-456. doi: 10.7326/L17-0401. Epub 2017 Dec 12.

Authors

Paul Breillat¹, Maylis Tourte¹, Pierre Romero¹, Gilles Hayem¹, Ilaria Padovano¹, Félicie Costantino¹, Maxime Breban¹

Affiliation

¹ Ambroise Paré Hospital, Boulogne, France (P.B., M.T., P.R., G.H., I.P., F.C., M.B.).

PMID: 29230477
DOI: 10.7326/L17-0401

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antirheumatic Agents / therapeutic use*
Dacryocystitis / drug therapy*
Dacryocystitis / etiology*
Female
Glucocorticoids / therapeutic use
Humans
Interleukin 1 Receptor Antagonist Protein / therapeutic use*
Methylprednisolone / therapeutic use
Middle Aged
Still's Disease, Adult-Onset / complications*
Still's Disease, Adult-Onset / drug therapy*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Glucocorticoids
Interleukin 1 Receptor Antagonist Protein
canakinumab
Methylprednisolone